Iguratimod has been reported to improve ACR20 response rates for patients with symptomatic clinical RA, and reduce the levels of IgG, IgM, and IgA in patients with RA without affecting the proliferation of B lymphocytes.29 This evidence concerns the gene CD40LG and rheumatoid arthritis.